HomeToday’s HighlightsThe Amgen/Novartis story. A Little Curiosity About Alder Biopharmaceuticals. The Amgen/Novartis story. A Little Curiosity About Alder Biopharmaceuticals. Today’s Highlights April 8, 2019 The Amgen/Novartis Story In May 2018 Amgen (AMGN) & Novartis (This content is for paid subscribers. Please click here to subscribe or here to log in. Today’s Highlights Alder BioPharmaceuticals (ALDR), Amgen (AMGN), Novartis (NVS) April 8, 2019 Tweet Pin It Other Articles Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease January 13, 2026 0 AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors January 12, 2026 0 Insmed Inc Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference January 9, 2026 0 Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline January 7, 2026 0